Group
About Us
HEMOLAB Dx fournit des technologies avancées pour le diagnostic médical et l’aide à la thérapeutique.
HEMOLAB Dx focuses on high clinical value-added segments, including HLA typing, molecular biology, and monoclonal antibody assays for optimizing targeted therapies.
Mission
To contribute to saving and sustaining lives through innovative and robust technologies
Vision
To be an essential, competent, and recognized local and regional player.
Values
ENTREPRENEURSHIP
PERSEVERANCE
HUMILITY
INTEGRITY
RESPECT
TEAM
History
Hemolab is a pioneer in hemodialysis in Morocco established in 1994. It diversified its activities in 1995 with Hemolab Pharma, becoming the first manufacturer of hemodialysis concentrate in the country. The acquisition of SPMCP in 2000 strengthened its position in the medical devices segment. Since then, the group has expanded to cover anaesthesia, resuscitation, oncology, biopharmaceuticals, diagnostics and water.
Activities
Transplantation
Cutting-edge, efficient, and robust technologies ensure successful grafts in transplantation.
The Luminex 100/200 system and FLEXMAP 3D platform enable simultaneous measurement of multiples analytes in a single reaction using a small sample volume, delivering rapid test results with high reliability. The Immucor range, distinguished by its user-friendly design and swift execution, facilitates HLA SSO typing tests, screening and identification of antibodies, and LSA tests. Hemolab Dx leads nationally in transplantation, partnering with institutions offering these essential tests. Hemolab Dx supports its partners in deploying technical platforms and interpreting results.
Molecular Biology
A wide array of extraction equipment and multiple kits are available for extracting nucleic acids from various biological samples.
There are flexible and efficient real-time PCR systems and kits for precise and swift diagnostics.
Hemolab Dx provides an extensive range of tests, particularly for sexually transmitted diseases, respiratory illnesses, and tropical diseases.
Rapid tests
Robust rapid tests for immediate initial diagnosis, allowing for qualitative detection of hepatitis virus and HIV from blood, serum, or plasma.
Hemolab Dx offers reliable tests that are WHO qualified.
Targeted Therapy
Monitoring circulating monoclonal antibodies for the optimization of targeted therapies.
agnostic kits for the multiplex quantification of proteins prescribed for the treatment of several diseases, allowing for personalized medical monitoring.
Promise provides a wide range for oncology, inflammation, transplantation, rheumatology, hemophilia, and hematology.
Next-Generation Sequencing (NGS)
Next-Generation Sequencing (NGS) technology applied to HLA typing and identification of multiple genes in oncology for precise diagnostics.
News
Annual Meeting of the Syndicate Chamber of Biologists 2024
Participation of HEMOLAB Dx at the 2nd edition of the annual meetings of the Syndicate Chamber of Biologists, held from February 1st to 3rd, 2024, at the Hyatt Regency in Casablanca.
Kidney Transplantation Day in 2022
We participated in the Kidney Transplantation Day in 2022 in Marrakech, where we had the pleasure of presenting the Luminex solution and the Immucor range to participants.
Partnership
Our partnerships have lasted for several decades, characterized by success resulting from strong synergies in terms of portfolio and channel.
These collaborations are meticulously studied, pre-planned, and executed methodically.
Our partners
References
